CO.DON is a biopharmaceutical company specializing in tissue engineering and the development and manufacturing of personalized cell therapies. The company provides regenerative treatments for joint cartilage defects to medical professionals and patients.
Subscribe to see CO DON AG CO.DON’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CO DON AG CO.DON is a biotech company headquartered in United Kingdom. Xcout recorded 2 job postings from CO DON AG CO.DON in the last 90 days.
Xcout recorded 2 job postings from CO DON AG CO.DON in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see CO DON AG CO.DON's hiring signals →
A few of CO DON AG CO.DON's closest competitors — see the full list of competitors and alternatives →
VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therapeutic solutions, including cell and gene therapies, specialized cell therapeutic procedures, cryopreservation of a patient's own immune cells, and CAR-T cell technology. Furthermore, VITA 34 manufactures advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells for experimental applications by specialized medical institutions. It also preserves stem cells from perinatal tissues and adult body fat, and provides contract manufacturing for pharmaceutical intermediates. Founded in 1997, VITA 34 AG is headquartered in Leipzig, Germany.
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Pharmicell develops and provides stem cell therapeutics, cell culture media, and biomedical products, alongside chemical raw materials and advanced industrial materials such as nucleosides and medical PEGs. The company serves patients, researchers, and medical institutions by offering stem cell-based treatments, contract development and manufacturing (CDMO) services, and stem cell-derived cosmetics.
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnishes comprehensive support for immuno-cell therapy, encompassing critical elements such as specialized technical expertise, advanced facilities, robust operational systems, essential materials, and skilled cell engineers. Furthermore, MEDINET actively manufactures regenerative medical products, investigational cell products, and other specified cell-based therapies. Its extensive value chain offerings also cover personnel training, facility and equipment design, operational management, standard operating procedure (SOP) preparation, logistics networks, information systems, purchasing and production management, stringent quality management and assurance, and technology transfer and process development. The firm actively collaborates with and supports medical institutions, research organizations, and biopharmaceutical companies in their endeavors to advance immuno-cell therapy.
BlueWhale Bio, Inc. is dedicated to accelerating the growth and adoption of cell-based therapies by pioneering next-generation cell therapy manufacturing.
Rentschler Biopharma SE is a contract development and manufacturing organization (CDMO). It is part of Dr. Rentschler Holding GmbH & Co. KG and its employees make up the majority of the 1300 workers employed by the parent organization.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.